Leiden: The Dutch city hosts one of the denser concentrations of biotech firms in northern Europe, and its companies share a complaint heard from Basel to Barcelona. Research funding exists, early-stage capital exists, and then the path from a promising molecule to a manufactured product runs into twenty-seven regulatory pathways and a financing gap European investors decline to fill.
The Commission answered on 26 May 2026 with a proposed Biotech Act. It identifies fragmented regulatory routes, limited late-stage financing and slow administrative procedures as the barriers stopping European research excellence from turning into industrial scale, and proposes a mix of regulatory simplification and capital.
The capital already exists. The Commission and the European Investment Bank have set out an initiative making 10 billion euro available to biotech and life sciences across 2026 and 2027, alongside a dedicated investment facility and targeted support for biomanufacturing projects. Money can move before legislation passes, and it has.
The legal plumbing moves slower. A regulation proposed in May 2026 will spend a year or more in Parliament and Council, and the simplification measures that matter most to firms, particularly on clinical trial authorisation and regulatory sandboxes, are precisely the ones that attract amendments. Companies will therefore spend the near term drawing on the finance while operating under the rules the Act is meant to replace.
That sequence is not obviously wrong. Capital shortages bind immediately and regulatory friction binds over years, so front-loading the money addresses the sharper constraint. It does mean the first tranche of investment flows into an environment the Commission has publicly described as unfit, which is an uncomfortable position to defend in a Parliament committee.
The scale of the sector argues for the attention. Biotechnology contributes roughly 40 billion euro to the European economy and accounts for more than 900,000 jobs, about three quarters of them in healthcare. Those are respectable figures that also understate the strategic question, because the issue is not current output but where the next generation of manufacturing capacity locates.
Clinical trials sit at the centre of that. Patient groups have argued for a framework that widens participation and spreads trial sites beyond the same handful of western European academic hospitals, on the grounds that access to a trial is often access to treatment. Their case aligns with the competitiveness argument, since a trial network that only functions in five member states is also a slow network.
Sceptics make a reasonable point about instrument choice. Europe has passed a series of sectoral acts on chips, critical raw materials and net zero industry, each pairing a target with a financing vehicle, and the delivery record is mixed. Adding biotech to that list invites the question of whether the constraint was ever the absence of a dedicated law. The Commission biotechnology pages set out the intended scope.
Firms in Leiden will take the finance regardless. The measure of the Act will be whether a company that raises a late-stage round in 2027 still finds it easier to manufacture in Boston than in Brabant, and nothing proposed in May settles that question yet.
